天際股份(002759.SZ):財務總監楊志軒完成減持1.405萬股 擬繼續減持不超1.05萬股
格隆匯1月4日丨天際股份(002759.SZ)公佈,公司近日收到財務總監楊志軒的吿知,截至2021年12月31日,楊志軒披露的減持計劃已實施完畢,其於2021年12月31日通過集中競價方式減持公司股份1.405萬股,佔公司總股本的0.0035%。楊志軒當前持有公司股份4.215萬股,佔公司總股本的0.0105%。
另外,楊志軒計劃自該公吿之日的6個月內以集中競價方式合計減持公司股份不超過1.0537萬股,即不超過公司總股本的0.0026%,集中競價交易應自該公吿之日起15個交易日後方可實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.